Should You Buy Guardant Health Inc (GH) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/28
Buy now for a long-term position. GH just pulled back ~4% on the day and is trading near a key support zone (~106.8), while fundamentals/news flow remain constructive (recent FDA companion diagnostic approval) and Wall Street price targets have been moving up. Momentum is weak short-term, but for a beginner long-term investor who doesn’t want to wait for a perfect entry, today’s dip is a reasonable entry point.
Technical Analysis
Trend is still broadly bullish on longer timeframes (SMA_5 > SMA_20 > SMA_200), but near-term momentum has turned bearish. RSI(6)=36.17 is weak (near oversold) and MACD histogram is negative and expanding (-0.149), consistent with the recent selloff. Price is below the pivot (112.95), so the immediate trend is “pullback within an uptrend.” Key levels: support S1=106.81 (then S2=103.01). Resistance: pivot 112.95, then R1=119.09. With price ~108.71, risk/reward is acceptable for a long-term entry as long as 106–103 holds.
Analyst Ratings and Price Target Trends
Recent trend: predominantly bullish with multiple price-target raises (Guggenheim to $135, Mizuho to $135, TD Cowen to $130, Stifel to $120, Canaccord to $125), reflecting improving confidence and/or updated forecasts. One notable counterpoint is Evercore ISI’s downgrade to In Line with a $105 target (still raised from $90), signaling valuation/expectations may be getting fuller after the run. Wall Street pros: strong growth outlook, catalyst path (publication/reimbursement + new clinical utility), and improving margins. Cons: still significant losses, reliance on continued volume/ASP growth, and sensitivity to earnings/guidance.
Influential/politician activity: No recent congress trading data available; hedge funds and insiders are reported as Neutral with no significant recent trend.
Intellectia Proprietary Trading Signals: AI Stock Picker: no signal on given stock today. SwingMax: No signal on given stock recently.
Wall Street analysts forecast GH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GH is 124.69 USD with a low forecast of 105 USD and a high forecast of 155 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast GH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GH is 124.69 USD with a low forecast of 105 USD and a high forecast of 155 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 109.730
Current: 109.730
